AZRX
Income statement / Annual
Last year (2020), AzurRx BioPharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2020, AzurRx BioPharma, Inc.'s net income was -$32.67 M.
See AzurRx BioPharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.89 M
|
$8.68 M
|
$4.99 M
|
$2.40 M
|
$2.50 M
|
$1.40 M
|
| General & Administrative Expenses |
$7.29 M
|
$6.06 M
|
$8.24 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.29 M
|
$6.06 M
|
$8.24 M
|
$0.00
|
$0.00
|
$0.00
|
| Other Expenses |
$20.54 M
|
$0.00
|
$210,000.00
|
$7.69 M
|
$4.13 M
|
-$4.73 M
|
| Operating Expenses |
$26.43 M
|
$14.74 M
|
$13.43 M
|
$10.08 M
|
$6.63 M
|
-$3.33 M
|
| Cost And Expenses |
$26.43 M
|
$14.74 M
|
$13.43 M
|
$10.08 M
|
$6.63 M
|
$4.73 M
|
| Interest Income |
$484.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$5.84 M
|
$433,939.00
|
$101,846.00
|
$875,199.00
|
$5.94 M
|
$1.59 M
|
| Depreciation & Amortization |
$37,797.00
|
$1.02 M
|
$798,446.00
|
$753,998.00
|
$734,500.00
|
$733,599.00
|
| EBITDA |
-$26.83 M |
-$13.72 M |
-$12.63 M |
-$9.47 M |
-$7.92 M |
-$3.61 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$6.24 M
|
-$433,939.00
|
-$101,846.00
|
-$1.02 M
|
-$7.97 M
|
-$1.20 M
|
| Income Before Tax |
-$32.67 M
|
-$15.18 M
|
-$13.53 M
|
-$11.10 M
|
-$14.59 M
|
-$5.93 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$398,084.00
|
$0.00
|
$0.00
|
-$140,000.00
|
-$2.03 M
|
$386,105.00
|
| Net Income |
-$32.67 M
|
-$15.18 M
|
-$13.53 M
|
-$11.10 M
|
-$14.59 M
|
-$5.93 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-5.90290331 |
-6.77 |
-8.77 |
-10.44 |
-22.43 |
-6.16 |
| EPS Diluted |
-5.90290331 |
-6.77 |
-8.77 |
-10.44 |
-22.43 |
-6.16 |
| Weighted Average Shares Out |
$5.53 M
|
$2.24 M
|
$1.54 M
|
$1.06 M
|
$650,479.00
|
$963,109.00
|
| Weighted Average Shares Out Diluted |
$5.53 M
|
$2.24 M
|
$1.54 M
|
$1.06 M
|
$650,479.00
|
$963,109.00
|
| Link |
|
|
|
|
|
|
